Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fesoterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 1.00 |
| ▸ | CHRM3 known ✓ | P20309 | 11/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fesoterodine SCHEMBL29366015 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3MAPTLMNA | |
| Fesoterodine SCHEMBL1808421 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3MAPTLMNA | |
| Fesoterodine SCHEMBL812986 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3MAPTLMNA | |
| Fesoterodine SCHEMBL15148766 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3MAPTLMNA | |
| Fesoterodine SCHEMBL3688110 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM3MAPTLMNA | |
| Fesoterodine SCHEMBL2474276 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM3MAPTLMNA | |
| Fesoterodine SCHEMBL2474910 | 0.98 | CHRM2 (0.96) | CHRM2CHRM1CHRM3MAPTLMNA | |
| Fesoterodine SCHEMBL2474905 | 0.98 | CHRM2 (0.96) | CHRM2CHRM1CHRM3MAPTLMNA | |
| Fesoterodine SCHEMBL814971 | 0.95 | CHRM2 (0.90) | CHRM2CHRM1CHRM3MAPTLMNA | |
| Fesoterodine SCHEMBL1993629 | 0.95 | CHRM2 (0.90) | CHRM2CHRM1CHRM3MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2985 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12638459-B2 | Method of diagnosing overactive bladder disorder | UNIVERSITY OF PORTSMOUTH HIGHER EDUCATION CORPORATION (GB) | 2026-05-26 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4719383-A2 | COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | MapLight Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-3731931-B1 | MODIFIED RELEASE FORMULATIONS OF FESOTERODINE | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2025-11-26 | — | — | EP | claimed |
| US-20250302814-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2025-10-02 | — | — | US | claimed |
| US-12427119-B2 | Transdermal delivery system including an interface mediator | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-09-30 | — | — | US | claimed |
| US-20250275924-A1 | Anticholinergic Agents and Muscarinic Agonists for the Treatment of Demodex Related Conditions | ATTILLAPS HOLDINGS INC. | 2025-09-04 | — | — | US | claimed |
| US-20250241933-A1 | METHODS OF TREATING SLEEP APNEA WITH A COMBINATION OF A CANNABINOID AND A CARBONIC ANHYDRASE INHIBITOR | APNIMED, INC. (DELAWARE) | 2025-07-31 | — | — | US | claimed |
| US-20250228832-A1 | METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. | 2025-07-17 | — | — | US | claimed |
| US-20050137194-A1 | Combination of selected opioids with other active compounds for treatment of urinary incontinence | GRUENENTHAL GMBH (DE) | 2005-06-23 | — | — | US | claimed |
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | claimed |
| WO-2004089872-A1 | HIGHLY PURE BASES OF 3,3-DIPHENYL PROPYLAMINE MONOESTERS | SCHWARZ PHARMA AG (DE) | 2004-10-21 | — | — | WO | claimed |
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG | 2004-09-23 | — | — | US | claimed |
| US-6713464-B1 | ANTIMUSCARINIC AGENTS WITH SUPERIOR PHARMACOKINETICS | SCHWARZ PHARMA AG (DE) | 2004-03-30 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1254890-A1 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2002-11-06 | — | — | EP | claimed |
| EP-1077912-B1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2002-07-03 | — | — | EP | claimed |
| EP-1077912-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058478-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 1999-11-18 | — | — | WO | claimed |